当前Biotech环境下公司生存策略讨论 | 2024 BioSpark年会

Chong is a Partner at F-Prime Capital.  He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of Skyline Therapeutics, K36 Therapeutics, and RareStone Group. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company’s Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia.  He received his B.S. in biology from Zhejiang University, China.

Erica Wang Esq. is the founding attorney for Veritas Law LLC.  Erica has been working in the legal field for over 25 years.  She is experienced of handling various legal issues in the fields of corporate operation and management, business collaborative transactions, mergers and acquisitions, labor employment, ethics compliance and dispute resolutions in China and the US.  Before founding Veritas Law LLC in Boston in 2024, Erica was the General Counsel of an AI-enabled drug discovery platform technology company, responsible for that company’s legal, compliance and intellectual property matters.  Previously, Erica had acted as General Counsel of Eli Lilly China, General Counsel of 3M Greater China Area and Assistant General Counsel of 3M Global Legal Affairs, as well as the Global General Counsel of Innovent Biologics.  Early in her career, Erica had practiced law in leading global law firms for a total of seven years (at Simmons & Simmons, and Baker McKenzie).

Erica received the Most Influential General Counsel Award of 2023 issued by Chambers and Partners, a world-renowned legal ranking institute.  Erica actively participates in non-profit social activities in China and the US.  She is a Board member of the Chinese Biopharmaceutical Association (New England Chapter).  She participated in the planning of many events for Boston Chinese Investment Club, the University Forum (formerly the Harvard Forum) and other non-profit organizations.  She often spoke at professional legal events, and startup financing platforms.  She also lectured to the Cheung Kong EMBA class on legal topics. Erica wrote a number of legal articles for LexisNexis, and was interviewed by top financial social media accounts frequently.    

Erica graduated from Fudan University Law School and the University of Chicago Law School.  She participated in Harvard Law School’s Visiting Scholar Program.  She is a registered lawyer in New York and Massachusetts.  She also holds the Chinese lawyer’s qualification.  Erica is based in the Boston area currently.  

John Wang, currently the Senior Vice President of the Simcere Pharmaceutical Group, is responsible for driving the BD&L and corporate development strategy, ensuring high-quality execution with a focus in the U.S. market, aligning with the goal of expanding Simcere's pipeline and commercial capability.

John was previously the Associate Vice President, Head of External Innovation, Immunology for Eli Lilly, leading collaboration, licensing, and acquisition deals in immunology therapeutic areas. Before that, John worked at Merck and Sanofi in Business Development, with primary focus in search and evaluation, due diligence, and alliance management. Early in John’s career, he worked in a research capacity in neuroscience at Wyeth.

John received his Ph.D degree in Pharmacology from the University of London, St George’s Hospital Medical School, UK; He conducted his postdoctoral training at Harvard Medical School and Boston University School of Medicine.

Marian Nakada has more than 30 years of experience in the pharmaceutical industry, starting her career at the laboratory bench at Centocor and moving to a research leadership role before Centocor’s acquisition by Johnson & Johnson.  She later transitioned to Janssen business development and later joined JJDC.   

Marian has a A.B. in Biology from Harvard and a Ph.D. in Pharmacology from the University of Pennsylvania.  She has authored 62 peer-reviewed publications and 14 book chapters and is a past reviewer for the NIH Pharmacology Study Section.   

She is currently on the Boards of Navitor and a stealth NewCo and is a Board Observer for ONL Therapeutics, Aetion, Iterative Health, Arkuda Therapeutics and Rome Therapeutics.  

Marian is co-founder of IgniteVC where she is working to champion change through its diversity & inclusion efforts. Outside work, Marian is a Board Member at InnerCity Weightlifting whose mission is to amplify the voice and agency of people who have been most impacted by systemic racism and mass incarceration.

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.

Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.

Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.